Spots Global Cancer Trial Database for A Study of MK-1484 as Monotherapy and in Combination With Pembrolizumab (MK-3475) In Advanced or Metastatic Solid Tumors (MK-1484-001)
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of MK-1484 as Monotherapy and in Combination With Pembrolizumab (MK-3475) In Advanced or Metastatic Solid Tumors (MK-1484-001)
Official Title: A Phase 1, Open-Label, Multicenter Study to Assess the Safety and Tolerability of MK-1484 as a Monotherapy and in Combination With Pembrolizumab in Adult Participants With Advanced or Metastatic Solid Tumors
Study ID: NCT05382325
Conditions
Study Description
Brief Summary: The purpose of this study is to assess the safety and tolerability and to establish a preliminary recommended Phase 2 dose (RP2D) of MK-1484 administered as monotherapy and in combination with pembrolizumab (MK-3475) in adults with advanced or metastatic solid tumors.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Sanford Cancer Center ( Site 0005), Sioux Falls, South Dakota, United States
NEXT Oncology ( Site 0001), San Antonio, Texas, United States
Princess Margaret Cancer Centre-Division of Medical Oncology and Hematology ( Site 0011), Toronto, Ontario, Canada
Rambam Health Care Campus-Oncology ( Site 0021), Haifa, , Israel
Sheba Medical Center-ONCOLOGY ( Site 0020), Ramat Gan, , Israel
Nederlands Kanker Instituut - Antoni van Leeuwenhoek (NKI-AVL) ( Site 0035), Amsterdam, Noord-Holland, Netherlands
Erasmus Medisch Centrum-Medical Oncology ( Site 0036), Rotterdam, Zuid-Holland, Netherlands
Universitair Medisch Centrum Utrecht-Medical Oncology ( Site 0037), Utrecht, , Netherlands
Contact Details
Name: Medical Director
Affiliation: Merck Sharp & Dohme LLC
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
